TRANSMIT	cket No.						
(Under 37 CFR 1.97(b) or 1.97(c))					2391.00011		
In Re Application Of: Rivka Abulafia-Lapid, et al.							
Application No	ation No. Filing Date Examiner Customer No.				Confirmation No.		
10/505,848							
Title:							
HSP70-DERIVED PEPTIDES AND USES THEREOF IN THE DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES							
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) 1. Image: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.							
		37 CFR 1.97(c)					
2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:							
☐ the statement specified in 37 CFR 1.97(e);							
OR .							
the fee set forth in 37 CFR 1.17(p).							
;							

TRANSMITTAL OF INFORTION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) P E					Docket No. 2391.00011			
In Re Application	n: Rivka Abulafia	Lapid, et al.	DEC O 6 2004	COFFICE OV				
Application No.	Filing Date	Examin	SKAT & TRADEM	Customer No.	Group Art Unit	Confirmation No.		
10/505,848					,			
Title:								
HSP70-DERIVED	PEPTIDES AND US	ES THEREOF IN 1	THE DIAGNO	OSIS AND TRE	CATMENT			
OF AUTOIMMUN	NE DISEASES		· · ·					
	(Only cor		nent of Fee	ee set forth in 37	CER 1 17(n))			
(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) ☐ A check in the amount of is attached. ☐ The Director is hereby authorized to charge and credit Deposit Account No. 11-1449 as described below. ☐ Charge the amount of ☐ Credit any overpayment. ☐ Charge any additional fee required. ☐ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be								
included o	n this form. Provide	e credit card infor	mation and	authorization	on PTO-2038.	Thot be		
account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. (Date)				Certificate of Mailing by First Class Mail I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on 12-3-04 (Date) (Date)				
Signature				Signature of Person Mailing Correspondence Connie Herty				
Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate Typed or Printed Name of Person Mailing Certificate						ertificate		
*This certificate may only be used if paying by deposit account. Dated: December 3, 2004 Signature Kenneth I. Kohn, Reg. No. 30,955 KOHN & ASSOCIATES, PLLC 30500 Northwestern Highway, Suite 410 Farmington Hills, Michigan 48334 (248) 539-5050								
cc:								

						She	et of _	SB/08 (2-92)	
Form PTO	D-1449 UEC	0 6 2004		Docket Number (Op 2391.00011	otional)	Application N 10/505,84			
INFORM	INFORMATION DISCLOSURE CONTINUE		ON	Applicant Rivka Abulafia-Lapid, et al.					
	IN AN APPLICAT	TON		Filing Date Group Art Unit			it		
	Use several sheets if ne	cessary)							
-		U.S. PA	ATEN	IT DOCUMEN	TS				
EXAMINER INITIAL			DATE		NAME CLASS			ING DATE PROPRIATE	
	5,439,688 8-		Orsol	ini et al.					
	5,733,877		I-98 Sato						
		:							
		FOREIGN	PAT	ENT DOCUM	ENTS				
						SUBCLASS	TRANSI	ATION	
	DOCKET NUMBER	DATE		COUNTRY	CLASS		YES	NO	
	OTHER DOC	UMENTS (Includ	ing Author, Title,	Date Pertin	ent Pages, Etc	:.)	L	
	Abulafia-Lapid, et a	l., "T Cell Prolife	erative	Responses of Type 1	l Diabetes Pa			ls to	
	Human hsp60 and its Peptides," J. Autoimmunity, 12:121-129 (1999). Atkinson, et al., "The Pathogenesis of Insulin-Dependent Diabetes Mellitus," New Engl. J. Med., 331:1428-1436 (1994).								
	Atkinson, et al., "Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes," <i>Lancet</i> , 339:458-459 (1992). Atkinson, et al., "Cellular Immunity to a Determinant Common to Glutamate Decarboxylase and Coxsackie Virus in Insulin-dependent Diabetes," <i>J. Clin. Invest.</i> , 94:2125-2129 (1994). Bach, J.F., "Insulin-Dependent Diabetes Mellitus as an Autoimmune Disease," <i>Endocrine Reviews</i> , 15:516-542 (1994). Elias, et al, "Treatment of Autoimmune Diabetes and Insulitis in NOD Mice With Heat Shock Protein 60 Peptide p277," <i>Diabetes</i> , 44:1132-1138 (1995).								
							ie Virus in		
, , ,	Elias, et al., "The hsp60 Peptide p277 Arrests the Autoimmune Diabetes Induced by the Toxin Streptozotocin," Diabetes, 45:1168-1172 (1996).								
	Elias, et al., "Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein," <i>Proc. Natl. Acad. Sci. USA</i> , 88:3088-91 (1991).								
	Elias, et al., "Autoimmune Diabetes Induced by the β-Cell," <i>Diabetes</i> , 43:992-998 (1994).								
	Elias, et al., "Peptide therapy for diabetes in NOD mice," Lancet, 343:704-706 (1994).								
	Elias, et al., "Hsp60 Peptide Therapy of NOD Mouse Diabetes Induces a Th2 Cytokine Burst and Downregulates								
	Autoimmunity to Various β-Cell Antigens," <i>Diabetes</i> , 46:758-764 (1997). Feige, et al., "Infection, autoimmunity and autoimmune disease," <i>EXS</i> , 77:359-373 (1996).								
	Harrison, et al., "Rea						nonuclear Cel	ls from	
	Subjects with Preclin Honeyman, et al., "T							253-274	
	(1993). Kaufman, "Heat sho	ck proteins and t	he imm	une response." Imm	unol. Todav	11:129-136 (19	990).		
	Kaufman, "Heat shock proteins and the immune response," <i>Immunol. Today</i> , 11:129-136 (1990). Kwok, et al., "Allele-Specific Motifs Characterize HLA-DQ Interactions with a Diabetes-Associated Peptide				ide				
Derived from Glutamic Acid Decarboxylase," J. Immunol., 156:2171-7 (1996).									

Rheum., 31:S13 (1988).

81:106-119 (1988).

Minota, et al., "Autoantibodies to Heat-Shock Proteins 70 in Systemic Lupus Erythematosus (SLE)," Arthritis

Minota, et al., "Autoantibodies to the Heat-Shock Protein hsp90 in Systemic Lupus Erythematosus," J. Clin. Invest.,

Lindquist, S., "The Heat-Shock Proteins," Annu. Rev. Genet., 22:631-677 (1988).

	Naquet, et al., "T Call Autoreactivity to Insulin in Diabetic and Related No. 140:2569-2578 (
	Polla, et al., "Hear snock proteins and immunity," Immunol. Today, 10:393-394 (1989).					
	Pugliese, et al., "endent Association BetweenPolymorphism and IDDM," Diabetes, 41:788-791 (1992).					
	Reizis, et al., "Molecular characterization of the diabetes - associated mouse MHC class II protein, I-Ag7," Internation. Immunol., 9(1):43-51 (1996).					
	Roep, B.O., "T-Cell Responses to Autoantigens in IDDM; The Search for the Holy Grail," <i>Diabetes</i> , 45:1147-1156 (1996).					
	Roep, et al., "T-cell reactivity to 38 kD insulin-secretory-granule protein in patients with recent-onset type 1 diabetes," <i>Lancet</i> , 337:1439-1441 (1991).					
	Roep, et al., "HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus," <i>Euro. J. Immunol.</i> , 26(6):1285-1289 (1996).					
	Rudy, et al., "Similar Peptides from Two β Cell Autoantigens, Proinsulin and Glutamic Acid Decarboxylase, Stimulate T Cells of Individuals at Risk for Insulin-Dependent Diabetes," <i>Molecular Medicine</i> , 1:625-633 (1995).					
	Salvetti, et al., "The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis," <i>J. Neuronimmunol.</i> , 65(2):143-153 (1996).					
	Van Buskirk, A. et al., "A peptide Binding Protein Having a Role in Antigen Presentation is a Member of The HSP70 Heat Shock Family," <i>J. Exp. Med.</i> , 170:1799-1809 (1989).					
EXAMINER	DATE CONSIDERED					
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.						

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE